Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
51 hedge funds and large institutions have $22.6M invested in Bellicum Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 21 closing their positions.
710% more call options, than puts
Call options by funds: $324K | Put options by funds: $40K
9% more capital invested
Capital invested by funds: $20.7M → $22.6M (+$1.83M)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
24% less funds holding
Funds holding: 67 → 51 (-16)
76% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$141K |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
+$130K |
| 3 |
D.E. Shaw & Co
New York
|
+$97.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$59.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.09M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$323K |
| 3 |
JP Morgan Chase
New York
|
-$286K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$210K |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$177K |
BLCM Hedge Fund Activity: Q4 2019 in Review
51 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2019, worth a combined $22.6M — up 8.8% from $20.7M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BLCM and 5 opened new positions — a net loss of 16 holders — while 17 trimmed existing stakes and 14 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $141K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.09M sold.
- 51 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2019, down from 67 in Q3 2019.
- Funds reported $22.6M of Bellicum Pharmaceuticals, Inc. stock for Q4 2019, up 8.8% quarter-over-quarter.
- 5 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2019 and 21 closed out, a net change of -16 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2019 was Jacobs Levy Equity Management, an estimated $141K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2019 was Armistice Capital, an estimated $1.09M sold.
Based on aggregated 13F filings for Q4 2019.